...
首页> 外文期刊>Therapeutic apheresis and dialysis: official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy >Chronic kidney disease progression to end stage renal disease: A single center experience of the role of the underlying kidney disease
【24h】

Chronic kidney disease progression to end stage renal disease: A single center experience of the role of the underlying kidney disease

机译:慢性肾脏病进展至终末期肾脏疾病:基础肾脏疾病作用的单一中心经验

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Chronic kidney disease (CKD) is common and several factors affect its progression to end-stage renal disease (ESRD). The main goal of our study was to assess the influence of underlying kidney disease and some other important factors during the time of CKD progression to ESRD. A retrospective study of 91 patients (57 men, 34 women; average age 57.7±13.2 years) was carried out. Patients were monitored at least one month before the first renal replacement treatment (RRT). Estimated glomerular filtration rate (eGFR) at first referral to nephrologist was determined by Modification of Diet in Renal Disease equation. Proteinuria was assessed semiquantitatively with dipsticks. Thirty-five patients (38.5%) had diabetic nephropathy (DN), 21 (23.1%) hypertensive nephrosclerosis (HN), 21 (23.1%) adult polycystic kidney disease (APKD) and 14 (15.4%) immunoglobulin A nephropathy (IgAN). Average eGFR at first referral for DN patients was 20.1, and then 23.4 for HN, 35.5 for APKD, and 36.4mL/min per 1,73m2 for IgAN patients. Average time between first nephrological visit and first RRT was 28.4 months for DN patients, 41 for HN, 80.8 for APKD, and 70.1 for IgAN patients. Comparison of all four groups of CKD patients showed that in patients with APKD and IgAN impairment of kidney function to ESRD had progressed statistically significantly slower (P0.001). When eGFR at referral, proteinuria, smoking, and renin-angiontensin-aldosterone blockade treatment had been added into the model, patients with APKD and IgAN had a statistically significant longer period between first nephrological visit and first RRT (P0.026). In comparison with patients with other underlying causes of CKD, patients with APKD and IgAN had a statistically significant slower progression rate of CKD to ESRD. Therapeutic Apheresis and Dialysis.
机译:慢性肾脏病(CKD)很常见,一些因素会影响其发展为终末期肾脏病(ESRD)。我们研究的主要目的是评估CKD演变为ESRD期间潜在的肾脏疾病和其他一些重要因素的影响。回顾性研究了91例患者(男57例,女34例;平均年龄57.7±13.2岁)。在首次肾脏替代治疗(RRT)之前至少一个月对患者进行了监测。肾脏疾病方程式中饮食的修改确定了初次转诊至肾脏科医生时的估计肾小球滤过率(eGFR)。用试纸半定量评估蛋白尿。 35例(38.5%)患有糖尿病肾病(DN),21例(23.1%)高血压肾硬化(HN),21例(23.1%)成人多囊肾病(APKD)和14例(15.4%)免疫球蛋白A肾病(IgAN) 。 DN患者初次转诊时的平均eGFR为20.1,然后HN为23.4,APKD为35.5,IgAN患者为每1,73m2 36.4mL / min。 DN患者首次肾科就诊与首次RRT之间的平均时间为28.4个月,HN为41岁,APKD为80.8个月,IgAN患者为70.1个月。比较所有四组CKD患者,发现APKD和IgAN肾功能损害的ESRD患者的病程进展在统计学上显着减慢(P <0.001)。当在转诊,蛋白尿,吸烟和肾素-血管紧张素-醛固酮阻滞治疗中加入eGFR时,APKD和IgAN的患者在首次肾脏病就诊和首次RRT之间具有统计学上显着的较长时间(P <0.026)。与患有CKD的其他潜在原因的患者相比,APKD和IgAN的患者从CKD到ESRD的进展具有统计学显着的减慢。治疗性血液透析和透析。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号